5. Nuvation Bio Inc. (NYSE:NUVB)
Number of Hedge Fund Holders — 42
Number of Billionaire Holders — 19
Nuvation Bio Inc. (NYSE: NUVB) combines product revenue from an approved lung cancer treatment with a developing precision-oncology portfolio.
IBTROZI generated $23.2 million in second-quarter net product revenue, increasing 25% from the preceding quarter. The medicine targets locally advanced or metastatic ROS1-positive non-small cell lung cancer, a genetically defined patient population.
Approximately 85% of the roughly 160 new patient starts during the quarter involved patients who had not previously received a tyrosine kinase inhibitor. That prescribing mix matters because earlier treatment positioning can influence the commercial opportunity, subject to treatment response and duration.
The latest pipeline expansion came on October 29. The company announced plans to add sites in six European countries to its pivotal Phase 3 SIGMA study of safusidenib, an investigational brain-penetrant IDH1 inhibitor.
The trial evaluates maintenance treatment following standard care in patients with IDH1-mutant astrocytoma with high-risk features. Its pivotal portion is planned to enroll approximately 300 patients, with progression-free survival assessed by blinded independent central review as the primary endpoint.
“Expanding SIGMA to sites across six European countries is an important step for patients,” CEO David Hung said.
The June balance sheet contained $661 million in cash, cash equivalents, and marketable securities. Those resources provide development capacity, while investors still need to examine the obligations associated with financing and the spending required to expand clinical operations.
For oncology-stock investors, the appeal is a combination of measurable commercial progress and additional pipeline opportunities. The central task is to assess how much future growth the stock’s valuation already assumes.
Ranking rationale: Nuvation Bio Inc. (NYSE: NUVB) ranks fifth with 19 billionaire holders. Sequential IBTROZI sales growth and the expansion of safusidenib’s pivotal program support inclusion, while prescribing momentum and clinical outcomes will shape future value.
